Abstract:9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one (KY‐31) displayed relatively low toxicity and retained anti‐inflammatory activity with a higher selectivity index compared to 9‐aminacrine (9‐AA). It may exert its anti‐inflammatory effects through the nuclear receptor subfamily 4 group A member 1 (NR4A1)/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway and inhibit the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). These findings support further development and exploration of 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one as a promising anti‐inflammatory compound for inflammatory conditions. 9‐aminacrine (9‐AA), an external antibacterial agent, possesses important bioactivities for the treatment of cancer, viruses, and prion diseases. Recent research has revealed that 9‐AA has anti‐inflammatory effects through the up‐regulation of nuclear receptor subfamily 4 group A member 1 (NR4A1), but it is highly cytotoxic. To mitigate its toxicity, three series of novel 9‐AA derivatives were synthesized. The toxicity of all compounds was assessed, and some of the less toxic compounds were tested for in vitro anti‐inflammatory activities, leading to the establishment of structure‐activity relationships. In particular, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one exhibited relatively low toxicity and retained anti‐inflammatory activity, with a higher selectivity index compared to 9‐AA (3.44 versus 0.68). Expression experiments of inflammatory mediators revealed that this compound not only inhibited the gene expression of pro‐inflammatory factors, but also promoted the gene expression of anti‐inflammatory factors. Preliminary mechanistic studies suggested that it exerted anti‐inflammatory effects through the NR4A1/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway. Furthermore, molecular docking studies indicating that it may exhibit anti‐inflammatory activity by inhibiting the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). Based on our data, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one with its low toxicity and anti‐inflammatory properties, holds promise for further development as an anti‐inflammatory agent.

Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis

Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives As Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.

Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives As Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase.

Design and Synthesis of Novel Double-Ring Conjugated Enones as Potent Anti-rheumatoid Arthritis Agents

Synthesis, XRD structural analysis and theoretical studies of a potential inhibitor against rheumatoid arthritis (RA)

Discovery a Series of Novel Inhibitors of Human Dihydroorotate Dehydrogenase: Biological Activity Evaluation and Molecular Docking.

Design, synthesis and anti-rheumatoid arthritis evaluation of double-ring conjugated enones

Design, synthesis and anti-rheumatoid arthritis activity of target TLR4 inhibitors

Novel Isatin-Based Hybrids As Potential Anti-Rheumatoid Arthritis Drug Candidates: Synthesis and Biological Evaluation

Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis

Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis

Akuammiline alkaloid derivatives: divergent synthesis and effect on the proliferation of rheumatoid arthritis fibroblast-like synoviocytes

Design, Synthesis, Biological Evaluation and Docking Study of A New Series of 9‐aminoacridine Derivatives as Anti‐inflammatory Agents

Therapeutic Potential of Aryl Hydrocarbon Receptor Ligands Derived from Natural Products in Rheumatoid Arthritis.

Synthesis and Anti-inflammatory Evaluation of Novel 1,2,3-Triazole Derivatives

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

Synthesis, Characterization And Cytotoxicity Of New Rotundic Acid Derivatives

Development of New Resolvin D1 Analogues for Osteoarthritis Therapy: Acellular and Computational Approaches to Study Their Antioxidant Activities

Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumatoid arthritis

Discovery of novel diaryl substituted isoquinolin-1( 2H )-one derivatives as hypoxia-inducible factor-1 signaling inhibitors for the treatment of rheumatoid arthritis

Design, Synthesis and Evaluation of 3-Amide-5-aryl Benzoic Acid Derivatives As Novel P2Y14R Antagonists with Potential High Efficiency Against Acute Gouty Arthritis.